Kornimate/medical-research-clean huggingface dataset:
nutritional therapy in late-onset pompe disease

Conditions: Pompe Disease; Muscle Loss; Obesity; Nutrition Poor; Lysosomal Storage Diseases; Glycogen Storage Disease Type II; Glycogen Storage Disease Type II Late Onset; Glycogen Storage Disease Type II, Adult

Summary: rationale: pompe disease (pd) is a recessive genetic disorder wherein the body cannot break down glycogen due to a mutation in the acid alpha glucosidase (gaa) gene, which encodes for acid alpha-glucosidase. the adult/late onset form (lopd) leads to glycogen accumulation and autophagic buildup, causing progressive muscle weakness that leads to wheelchair dependence, reduced quality of life and premature death due to cardiorespiratory insufficiency. while nutritional strategies, such as the low carbohydrate/high protein and ketogenic diets, have been used clinically, they are difficult to maintain and have limited benefits. multi-ingredient supplementation (mis) allows for targeting of several underlying pathogenic pathways and may be more convenient than traditional dietary strategies, thereby improving both adherence and lopd pathology.

design and intervention: the present study is a 4-month randomized, double-blind, placebo-controlled clinical trial (rct) with sampling pre and post intervention in late onset pompe disease patients undergoing enzyme replacement therapy (ert) (21-90 years of age). each patient will be randomized into either a pompe-targeted multi-ingredient supplement (pdt-mis; high-quality proteins, antioxidants, plant extracts, vitamins, and omega-3 fatty acids,) or placebo (pla; collagen, safflower, and cellulose) group and then undergo four months of daily supplementation with concurrent rehabilitative exercise training (mixed cardio and strength four days/week) and respiratory muscle training (four days/week). general research aims and hypothesis: the purpose of this study is to investigate the benefits of pdt-mis on muscle and blood pathology, muscle function, respiratory capacity, and health-related quality of life (hrqol) in lopd patients on enzyme replacement therapy (ert). it is generally hypothesized that ptd-mis will mitigate mitochondrial dysfunction, oxidative damage, inflammation and alleviate 'autophagic block' in skeletal muscle of lopd patients. pdt-mis may therefore improve muscle pathology by affecting several cell pathways simultaneously, and thereby enhance muscle function, respiratory capacity, and hrqol of lopd patients.

Eligibility criteria:
inclusion criteria: * genetically confirmed lopd * have undergone enzyme replacement therapy for at least three months. * physically capable of doing rehabilitative exercise, respiratory muscle training, and the clinical tests described herein. exclusion criteria: * dairy protein allergy * renal disease (creatinine \> 140) * attempting pregnancy or currently pregnant * current supplementation

Keywords: muscle supplements antioxidants whey casein vitamin d creatine calcium omega-3 green coffee bean green tea coq10 alpha-lipoic acid vitamin e weight loss obesity muscle strength 6-meter walk test pompe disease oxidative stress mitochondria autophagy glycogen forskolin beet root performance
boswellia serrata extract in acute diarrhea

Conditions: Acute Diarrhea; Boswellia Serrata

Summary: acute diarrhea is a frequent problem worldwide, mostly due to gastrointestinal infections or food poisoning. boswellia serrata could be active in the treatment of acute diarrhea due to its an-ti-inflammatory, antispasmodic and antimicrobial activity.


Eligibility criteria:
inclusion criteria: * presence of acute diarrhea of mild to moderate severity exclusion criteria: * patients with long term diarrhea * iatrogenic diarrhea * symptoms of functional gut disease or severe inter-current diseases * severe diarrhea and dehydration requiring hospitalization and intravenous treatment * subjects with high temperature (\> 38.5° c) * subjects treated by other anti-diarrheal and antibiotic drugs in the last 24 hours * severely malnourished subjects * pregnant women
effect of visceral osteopathic manipulations on low back pain

Conditions: Low Back Pain

Summary: forty female patients with age ranging from 30-40 years old were suffering from low back pain due to visceral dysfunctions participated in this study. they were recruited from a private clinic. they were assigned into two groups equal in number; group (a): included twenty patients who received osteopathic manipulative techniques, 1 session per week for 3 weeks, and group (b): included twenty patients who received only analgesic drugs.

twenty patients received osteopathic manipulative techniques including suboccipital release technique, diaphragmatic release.,mesentery release and colonic manipulation were applied to the study group according to the patients' needs. the treatment program comprised a total of 3 sessions for 3 weeks at one session per week for an average of 50 minutes per session. twenty patients in the second group (control ) took only analgesics during the three weeks.

Eligibility criteria:
inclusion criteria: * non-specific low back pain for more than 12 weeks exclusion criteria: * malignant tumor * pregnancy * acute ischemic bowel disease, * intestinal obstruction, * surgery in the last six months
gynaecological follow-up of women with down syndrom aged 18 to 30 in france

Conditions: Down Syndrome

Summary: gynaecological check-ups for women are recommended in france. however, some groups of the population are affected by a lack or absence of medical surveillance. in france, there are one million people with an intellectual disability, including 50,000 with down syndrome. although this disability causes numerous physical and psychological deficits, no gynaecological consequences have yet been demonstrated. regular gynaecological check-ups are therefore necessary, according to french recommendations. however, several studies have shown that women with mental illness receive less or no gynaecological care.

the aim is to describe the gynaecological follow-up of women with down syndrom in france.

Eligibility criteria:
inclusion criteria: * women with down's syndrome, * aged between 18 and 30, * whether or not they are being followed up in a medical facility, * who agree to take part in the study. exclusion criteria: * women with a disability other than down's syndrome * not agreeing to take part in the study

Keywords: gynaecological follow-up down syndrome women
horse chestnut seed extract for lymphedema

Conditions: Lymphedema of Arm

Summary: to help treat lymphedema of the arm in breast cancer survivors with horse chestnut seed extract

the objectives of this study are to evaluate the effectiveness of escin (as horse chestnut seed extract) for arm lymphedema in women following treatment for breast cancer, to evaluate the accuracy and sensitivity of bioelectric impedance as a measurement of lymphedema of the arm, and to validate the proposed arm lymphedema quality-of-life questionnaire.

Eligibility criteria:
inclusion criteria: * patient demonstrates unilateral (ipsilateral to breast cancer resection side) lymphedema of the upper extremity. an extravascular water ratio of ³1.1/1 between the affected vs normal arm using multiple-frequency bioelectric impedance will be used as a criterion for lymphedema. there is not upper limit to the extent of arm volume (lymphedema) * patient is greater than 6 months from last surgical and/or radiation treatment to the affected axilla. exclusion criteria: * patients may not be receiving or be scheduled to receive cytotoxic or radiation chemotherapy treatment while on this lymphedema study (last chemotherapy \> 4 weeks prior). women who are being treated adjuvantly with tamoxifen, raloxifene, or an aromatase inhibitor remain eligible * patients with a history of recurrent (more than 1 episode) arm cellulitis, prior or existing venous clot, or considered to have "woody" fibrosis of the affected arm are not eligible. antibiotics used to treat any prior episode of cellulitis must have be completed no more recently than 3 months prior to initial screening.
losartan in hypertensive men and women with sleep apnea before and on continuous positive airway pressure (cpap) treatment

Conditions: Hypertension; Sleep Apnea

Summary: obstructive sleep apnea (osa) is a highly prevalent condition in hypertensive patients. the renin-angiotension-aldosterone-system (raas) has a central role in blood pressure control. an angiotensin-ii-antagonist, losartan, is an effective antihypertensive drug. however, some patients respond to this drug worse than the others, and it is a clinical praxis to either increase the dosage and/or add another drug. there is limited data regarding the impact of antihypertensive drugs in osa patients, i.e., whether or not osa may constitute the subgroup of therapy-resistent hypertensive patients. in the literature, there is no data, either, whether or not cpap treatment may have an additive blood pressure lowering impact in this certain subgroup.

osa is a highly prevalent condition in hypertensive patients and the prevalence is even higher in patients with drug-resistant hypertension. the renin-angiotension-aldosterone-system (raas) has a central role in blood pressure control. an angiotensin-ii-antagonist, losartan, has an effective antihypertensive drug. however, some patients respond to this drug worse than the others, and it is a clinical praxis to either increase the dosage and/or add another drug. there is limited data regarding the impact of antihypertensive drugs in osa patients, i.e., whether or not osa may constitute the subgroup of therapy-resistent hypertensive patients. in the literature, there is no data, either, whether or not cpap treatment may have an additive blood pressure lowering impact in this certain subgroup. the investigators will include 90 otherwise healthy, untreated hypertensive men and women(age 50-69 yrs, body-mass-index \<35 kg/m2; 60 patients with osa, 30 non-osa) as described above. before start of treatment, fasting blood samples will be drawn regarding the neuroendocrine hormones (adrenaline, noradrenaline, plasma renin activity, angiotensin ii,aldosterone, pro-bnp) and cardiovascular biomarkers (crp,interleukines, cytokines). all subjects will start with losartan 50 mg and 24 h- blood-pressure response and blood sample analysis will be compared between osa and non-osa subjects after 6 weeks of treatment. in the second 6-week period, all subjects will continue with losartan while the half of the osa group (n=30) will be randomized to cpap and the other 30 patients will continue with losartan only.

Eligibility criteria:
inclusion criteria: * body mass index \<35 kg/m2 * systolic blood pressure \>=140 mmhg and/or diastolic blood pressure \>=95 mmhg * no known clinical disease except hypertension * no cardiovascular medication * apnea-hypopnea index \ =15/h (osa) exclusion criteria: * manifest diabetes, liver- or kidney disease signs of atrial fibrillation or former myocardial infarction at electrocardiogram

Keywords: hypertension sleep apnea angiotensin ii antagonist cpap
heart rate, baroreflex sensitivity and cardiovascular morbidity and mortality in the population

Conditions: Community Based Study; Cardiovascular Disease; Sudden Death; Blood Pressure

Summary: the aim of the present paris prospective study iii (pps3) is (1) to assess the determinants of the regulation of heart rate and blood pressure variations and carotid properties (under different physiologic stimulations) and (2) to evaluate the respective contribution of heart rate, blood pressure variations and carotid properties to cardiovascular morbidity and mortality including sudden death during 10 years at least in healthy considered subjects.

overall, 10 157 men and women have been recruited during may 2008 and june 2012 for an extensive clinical examination including a 2h holter electrocardiography (ecg), a carotid doppler echo tracking, a step test, as well as blood and dna collections. since then, the cardiovascular morbidity and mortality of the participants is being followed up for 10 years at least and will continue up to 2032.

Eligibility criteria:
inclusion criteria: * 50-75 years, french speaking, given consent for genetic analysis, * written consent for participating in the study exclusion criteria: * \ 75 years, * no french speaking, * current pregnancy, * chronic severe disease, * disagreement for genetic analysis, * step test considered as non possible or non advisable by medical decision.

Keywords: epidemiology risk factors heart rate baroreflex sensitivity sudden death
high-flow nasal oxygenation for open mouth

Conditions: Anesthesia, General; Apnea

Summary: this study aims to evaluate the effect of high-flow nasal oxygenation on safe apnea time for children undergoing general anesthesia, with their mouth open.

oxygenation via high-flow nasal cannula is gaining popularity in various clinical settings. it is known to increase apnea time for apneic patients including children. however, high-flow nasal cannula is known to be ineffective when the patient's mouth is kept open. when trying to intubate the patient during induction of anesthesia, the patient should be apneic with administration of neuromuscular blocking agent, and the mouth should be open for introduction of laryngoscope. we designed a prospective randomized controlled study to evaluate the effect of high-flow nasal oxygenation in the aforementioned setting for trying to intubate the patient.

Eligibility criteria:
inclusion criteria: * children younger than 11 years old scheduled to undergo surgery under general anesthesia, with american society of anesthesiologists physical status 1 or 2. exclusion criteria: * refusal to enrollment from one or more of legal guardians of the patient * children who are planned to use supraglottic airway device * children with upper respiratory tract infection or pulmonary interstitial disease * preterm babies under 40 weeks of postconceptual age * children who are expected to have difficult airway for bag-mask ventilation

Keywords: high-flow nasal cannula preoxygenation apnea time general anesthesia
effect of apical patency and local corticosteroid on pain and neuropeptides release in patients with symptomatic irreversible pulpitis: a randomized clinical trial

Conditions: Postoperative Pain; Symptomatic Irreversible Pulpitis

Summary: the goal of this randomized clinical trial is to learn the effect of using local corticosteroids and maintaining apical patency in reducing post-preparation pain in patients with acute irreversible pulpitis in molar teeth. the main question it aims to answer is: • how effective are using local corticosteroids and maintaining apical patency in reducing post-preparation pain in patients with acute irreversible pulpitis? participants will be asked to fill a visual analogue scale to record their pain, after receiving a root canal treatment while using local corticosteroids or not as well as maintaining apical patency or not. researchers will compare the use of corticosteroids and maintaining apical patency in reducing post-operative pain.


Eligibility criteria:
inclusion criteria: * symptomatic acute irreversible pulpitis in molar teeth. * normal periapical condition including periapical radiography with minimal widening of periodontal ligament. * normal probing depth. * no medical condition. * no contraindication for administration of corticosteroids and local anesthesia. exclusion criteria: * facial or oral paresthesia. * pregnancy \& breastfeeding. * unrestorable tooth. * marginal periodontal disease. * presence of a crown on the tooth involved. * over instrumentation during root canal treatment. * long-term use of corticosteroids. * false-positive cases of sensibility test with necrosis discovered after gaining access to the tooth. * cases requiring intrapulpal injection to promote anesthesia.

Keywords: pulpitis postoperative pain vas
weight changes in parkinsonian patients, treated with deep brain stimulation

Conditions: Parkinson Disease

Summary: the aim of this trial is to verify that neurostimulated parkinsonian patients gain weight and to study its link with an energetic balance change.

the aim of this trial is to verify that neurostimulated parkinsonian patients gain weight and to study its link with an energetic balance change. twenty parkinsonian patients will be randomised : the delay between inclusion and neurostimulation wil be lengthened 3 months for one group, compared to the second one. the energy expenditure, at rest and after ingestion of a test meal, will be compared between the group of patients that had been neurostimulated and the group whose intervention has been postponed. weight changes, energy intake, leptin level, neurophysiological parameters will be compared between both groups, and the nature and repartition of the weight gain will be assessed in the neurostimulated group. an eventual link between motor factors, pharmacological factors, and gain weight will be studied.

Eligibility criteria:
inclusion criteria: * age between 35 and 70; male or female; parkinson disease, with levo dopa response (at least 30%); severe but stable incapacity; no dementia, no psychosis, no depression; normal brain scanner done during the last 2 years. exclusion criteria: * diabetes thyroid disease pacemaker coagulation troubles previous drug abuse

Keywords: parkinson deep subthalamic stimulation pharmacological treatment
the unstable thoracic cage injury

Conditions: Thoracic Spine Fracture; Concomitant Sternal Fracture

Summary: * analysis of patient data and computed tomography scan of polytraumatized patients thoracic spine fractures * a concomitant sternal fracture was identified an indicator for an unstable thoracic spine fracture

previous studies stated, that sternal fractures can be regarded as an indicator for thoracic spine fractures and described the combined injury pattern of thoracic spine fracture and sternal fracture as "upper thoracic cage injury". but literature research is lacking data that in patients with a thoracic cage injury a highly unstable thoracic spine fracture can be expected. in a large cohort of 130 patients with a thoracic spine fracture and concomitant sternal fracture the investigators analyzed the injury pattern and evaluated associated injuries, trauma mechanism, and clinical outcome. the investigators could prove that in patients with a thoracic cage injury the concomitant sternal fracture may be regarded as an indicator for an unstable thoracic spine fracture, which requires surgical stabilization. furthermore the analysis revealed that even a highly rotationally unstable type c fracture has to be expected, if sternal and thoracic spine fractures are located in the same segment.

Eligibility criteria:
inclusion criteria: * sternal fracture and concomitant thoracic spine fracture * injury severity scale ≥ 16 * age under 50 years * presence of a whole body computed-tomography (ct-scan) performed at admission of the patient to the hospital exclusion criteria: * missing consent * incomplete patient data

Keywords: sternal fracture thoracic spine fracture thoracic cage injury
additional autoimmune diseases with type 1 diabetes in pediatrics at diabetes diagnosis and during follow-up

Conditions: Type 1 Diabetes; Autoimmune Diseases; Hashimoto Disease; Graves Disease; Celiac Disease; Addison Disease; Vitiligo

Summary: this study aims to describe the prevalence of additional autoimmune diseases and their specific antibodies at type 1 diabetes (t1d) diagnosis, and their incidence rate during follow-up, for children and adolescents. it also aims to describe the characteristics of the pediatric cohort followed since 2014 for type 1 diabetes by one of france's centers of reference for paediatric diabetes.


Eligibility criteria:
inclusion criteria: * patients with type 1 diabetes diagnosed with the following criteria: (i) classic symptoms of diabetes or hyperglycemic crisis, with plasma glucose concentration ≥11.1 mmol/l (200 mg/dl), or (ii) fasting plasma glucose ≥7.0 mmol/l (≥126 mg/dl) ; and (iii) presence of diabetes associated autoantibodies : ica, gad, ia2, iaa and/or znt8 * age \< 18 years old at type 1 diabetes diagnostic * type 1 diabetes diagnosed between 2014-01-01 and 2021-02-01 exclusion criteria: * type 1 diabetes diagnostic not certain

Keywords: type 1 diabetes autoimmune diseases pediatrics children adolescents
using triamcinolone acetonide to reduce pain after scleral buckle surgery

Conditions: Retinal Detachment

Summary: purpose: scleral buckle surgery is a widely used ophthalmic surgery for the correction of rhegmatogenous retinal detachment. studies suggest that eye pain is a common and underestimated occurrence after scleral buckle surgery, but as of yet, there is no definitive management method for reducing pain following scleral buckle surgery. the investigators aim to control pain following scleral buckle surgery with sub-tenon's irrigation with triamcinolone acetonide at the time of surgery. using a randomized prospective clinical study, the investigators test if this technique will reduce the pain, nausea/vomiting, and analgesic use caused by scleral buckle surgery. methods: forty-eight patients undergoing scleral buckle surgery will be randomized into two groups. the experimental group receives a sub-tenon irrigation of 1 cc 40mg/ml triamcinolone acetonide around the base of the scleral buckle (0.25 cc in each quadrant) at time of operation. the control group does not receive any triamcinolone irrigation. pain scores are measured 1 day post-operatively via 11-pt numerical rating scale as the primary outcome. the nausea/vomiting score is measured 1 day post-operatively via standard 6-pt scale. patients track pain medication use via pill count. values will be measured again at 1-2-week and 6 months post-op.


Eligibility criteria:
inclusion criteria: * patient must have rhegmatogenous retinal detachment and be scheduled to undergo scleral buckle surgery for correction exclusion criteria: * advanced glaucoma * history of corticosteroid responsive elevation in iop * allergy to triamcinolone acetonide or other corticosteroids * pre-existing chronic pain disorders * herpes zoster * prior corneal allograft * allergy to local anesthetic or penicillin * patients unable to consent on own behalf * patients unable to communicate pain and nausea levels * pregnancy * incarceration

Keywords: scleral buckle triamcinolone acetonide